Literature DB >> 35747574

Comprehensive Thrombophilia Evaluation in Cerebral Venous Thrombosis: A Single Center Cross Sectional Study.

Rajiv Kumar1, Pulikottil Wilson Vinny2, Vishnu G Nair3, Rajesh Jakku3.   

Abstract

In patients with Cerebral Venous Thrombosis (CVT), inherited and acquired thrombophilic conditions have been studied either individually or as subset of a comprehensive evaluation. None of the studies have included a comprehensive evaluation of all the known associations. The associations for various conditions have been found to differ significantly between the Indian and the Western population. We defined a Comprehensive Thrombophilia panel (inherited and acquired) comprising of 13 thrombophilic conditions to include all the relevant known associations in CVT. All patients in this cross-sectional study were evaluated as per the defined protocol during the three-year study period. We evaluated 42 patients of CVT for presence of inherited and acquired thrombophilic conditions. The mean age of the study population was 38.4 yrs. An inherited or an acquired thrombophilic condition was diagnosed in 76% patients. Hyperhomocysteinemia and raised factor VIII levels were the most common conditions, seen in 38% and 35.7% patients respectively. MTHFR mutation was seen in 21% patients. Protein S deficiency was seen in 7% patients. Factor V Leiden and JAK2 positive MPN were seen in 2.3% cases. We did not detect any patients with Protein C deficiency, APLA syndrome, anti-thrombin deficiency, PG20210A mutation or PNH. PAI-1 polymorphism was not included in the protocol as its role is controversial and it has not been established in Indian studies. There is an urgent need for Comprehensive Thrombophilia testing in a larger population of CVT patients to better delineate the spectrum of associated thrombophilic conditions. Such a study is bound to impact therapy and prognosis of CVT. © Indian Society of Hematology and Blood Transfusion 2021.

Entities:  

Keywords:  CVT; Hyperhomocysteinemia; MTHFR; Thrombophilia; fVIII

Year:  2021        PMID: 35747574      PMCID: PMC9209621          DOI: 10.1007/s12288-021-01480-3

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.915


  30 in total

1.  Elevated factor VIII increases the risk of cerebral venous thrombosis: a case-control study.

Authors:  Loes Vecht; Susanna M Zuurbier; Joost C M Meijers; Jonathan M Coutinho
Journal:  J Neurol       Date:  2018-05-08       Impact factor: 4.849

Review 2.  Cerebral venous thrombosis and thrombophilia: a systematic review and meta-analysis.

Authors:  Mandy N Lauw; Stefano Barco; Jonathan M Coutinho; Saskia Middeldorp
Journal:  Semin Thromb Hemost       Date:  2013-10-15       Impact factor: 4.180

3.  Plasma factor VIII in non-puerperal cerebral venous thrombosis: a prospective case-control study.

Authors:  Ravi K Anadure; Dindagur Nagaraja; Rita Christopher
Journal:  J Neurol Sci       Date:  2014-02-11       Impact factor: 3.181

Review 4.  Treatment of unusual thrombotic manifestations.

Authors:  Maria Abbattista; Marco Capecchi; Ida Martinelli
Journal:  Blood       Date:  2020-01-30       Impact factor: 22.113

5.  Homocysteine and thrombosis: guilt by association?

Authors:  William P Fay
Journal:  Blood       Date:  2012-03-29       Impact factor: 22.113

Review 6.  Natural history of cerebral vein thrombosis: a systematic review.

Authors:  Francesco Dentali; Monica Gianni; Mark A Crowther; Walter Ageno
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

7.  Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?

Authors:  Matthias Lamy; Paola Palazzo; Pierre Agius; Jean Claude Chomel; Jonathan Ciron; Aline Berthomet; Paul Cantagrel; Julia Prigent; Pierre Ingrand; Mathieu Puyade; Jean-Philippe Neau
Journal:  Cerebrovasc Dis       Date:  2017-06-14       Impact factor: 2.762

8.  Hyperhomocysteinemia in cerebral vein thrombosis.

Authors:  Ida Martinelli; Tullia Battaglioli; Paola Pedotti; Marco Cattaneo; Pier M Mannucci
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

9.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

10.  Hyperhomocysteinemia and Risk of First Venous Thrombosis: The Influence of (Unmeasured) Confounding Factors.

Authors:  Monica Ospina-Romero; Suzanne C Cannegieter; Martin den Heijer; Carine J M Doggen; Frits R Rosendaal; Willem M Lijfering
Journal:  Am J Epidemiol       Date:  2018-07-01       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.